Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Robotic Surgery Stocks to Buy

In this article, we will list the 5 Best Robotic Surgery Stocks to Buy. Please visit 7 Best Robotic Surgery Stocks to Buy if you would like to see the extended list and the methodology behind it.

5. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Number of Hedge Fund Holders: 41

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best robotic surgery stocks to buy. Canaccord cut the price target on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to $83 from $93 on April 29, and maintained a Buy rating on the shares. The firm stated that the company delivered a solid fiscal Q1 to start the year, and as it relates to its US go-to-market transformation, the company called out modest disruption in Q1 within expectations as it continued to execute the changes. This occurred with specialization increasing to ~30% of the force, non-dedicated reps declining to below 60%, and early productivity gains in transitioned territories.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also received a rating update from Citizens on April 29. The firm cut the price target on the stock to $105 from $120, maintaining an Outperform rating on the shares. The firm stated that the company delivered stronger EPS outperformance in fiscal Q1 and a modest revenue beat, which was largely driven by tariff-related benefits boosting margins. It further told investors in a research note that although core performance was mixed, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) raised its EPS guidance and maintained its revenue outlook to reflect tariff impacts. According to Citizens, 2026 is still viewed as a transitional year.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) designs, manufactures, and markets orthopedic reconstructive products. It also offers biologics, extremities, sports medicine, dental implants, trauma products, and related surgical products. The company operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific.

4. Globus Medical, Inc. (NYSE:GMED)

Number of Hedge Fund Holders: 42

Globus Medical, Inc. (NYSE:GMED) is one of the best robotic surgery stocks to buy. Wells Fargo cut the price target on Globus Medical, Inc. (NYSE:GMED) to $103 from $104 on May 8, maintaining an Overweight rating on the shares and noting that the company reported fiscal Q1 sales and EPS well ahead of its consensus and estimates.

In its financial results for fiscal Q1 2026, Globus Medical, Inc. (NYSE:GMED) reported worldwide net sales of $759.9 million, reflecting an increase of 27.0%, or an increase of 25.5% on a constant currency basis. Management further reported that base business, excluding Nevro, net sales were $677.2 million, up 13.2%, or an increase of 11.2% on a constant currency basis. The company headed off a strong start to the year, with record Q1 earnings and organic revenue growth driven by share gains and procedural volume strength in core spine. Keith Pfeil, President and Chief Executive Officer, also stated that Enabling Technologies delivered against its pipeline and continued to expand the company’s customer base.

Globus Medical, Inc. (NYSE:GMED) is a medical device company involved in the development and commercialization of healthcare solutions. The company classifies its products into Innovative Fusion and Disruptive Technology, and operates through the United States and International geographical segments.

3. Medtronic plc (NYSE:MDT)

Number of Hedge Fund Holders: 63

Medtronic plc (NYSE:MDT) is one of the best robotic surgery stocks to buy. Medtronic plc (NYSE:MDT) announced on May 20 its intention to acquire SPR Therapeutics, Inc. (SPR), which is a privately held medical technology company that holds a leading position in temporary, percutaneous peripheral nerve stimulation therapies for chronic pain management. Management stated that the transaction comprises an upfront cash payment of approximately $650 million for all the outstanding equity in SPR, and is subject to customary closing conditions and regulatory approvals.

Medtronic plc (NYSE:MDT) stated that the acquisition continues to support the company’s momentum in building out its core franchises through strategic deals and is expected to close within the first half of the company’s fiscal year 2027, which officially began on April 25.

In a separate development, Medtronic plc (NYSE:MDT) announced on April 28 that it received the CE mark for the Stealth AXiS™ surgical system, indicated for spine and cranial procedures. Management stated that the system is a next-generation platform that amalgamates navigation, planning, and robotics into a single intelligent system and is scalable across multiple surgical specialties for the company.

Medtronic plc (NYSE:MDT) is a medical technology company that manufactures, distributes, and sells device-based medical services and therapies. It operates under four primary segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

2. Stryker Corporation (NYSE:SYK)

Number of Hedge Fund Holders: 67

Stryker Corporation (NYSE:SYK) is one of the best robotic surgery stocks to buy. Barclays cut the price target on Stryker Corporation (NYSE:SYK) to $394 from $469 on May 4, maintaining an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 results were mixed and below the Street’s estimates. It also stated that a “significant back-end loaded ramp” is required to attain the company’s full-year guidance for the target cut.

In a separate development, Truist cut the price target on Stryker Corporation (NYSE:SYK) to $380 from $395 on April 15, reaffirming a Hold rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated in a research note that a premium valuation is justified for the stock given its view of the company’s high-quality, above-average revenue growth profile. However, it also prefers to have higher conviction in EPS upside and faster earnings growth potential.

Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services that help improve patient and health outcomes. Its operations are divided into the MedSurg and Neurotechnology and the Orthopedics and Spine segments.

1. Intuitive Surgical, Inc. (NASDAQ:ISRG)

Number of Hedge Fund Holders: 109

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best robotic surgery stocks to buy. BofA cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $520 from $650 on May 18, reiterating a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies the week before in Las Vegas, it updated several price targets for “the new reality of medtech valuations” in a year of few product cycles, inflation kicking up post-war, ACA and utilization worries, and “data centers over healthcare”.

For additional reference, in its financial results for fiscal Q1, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported that worldwide procedures for da Vinci and Ion combined grew around 17% compared to fiscal Q1 2025, with Da Vinci procedures growing approximately 16%, and Ion procedures growing approximately 39%. Revenue for the quarter came up to $2.77 billion, up 23% compared to $2.25 billion in the prior year period. The company also reported that it placed 431 da Vinci surgical systems, compared with 367 in fiscal Q1 2025.

Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems.

While we acknowledge the potential of ISRG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ISRG and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.